How are energy investors positioned?
BRISBANE, Calif. — Adam Dubow, General Counsel of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN), a $1.25 billion market cap biopharmaceutical company, reported selling 4,646 shares of the company’s common stock on February 18, according to a recent filing with the Securities and Exchange Commission. The shares were sold at an average price of $11.963, amounting to a total transaction value of $55,580. The stock currently trades at $12.43, near its InvestingPro Fair Value.
The sale was executed to cover tax liabilities associated with the vesting of restricted stock units (RSUs), as noted in the filing. Following this transaction, Dubow holds 39,602 shares of Day One Biopharmaceuticals.
Earlier, on February 15, Dubow acquired 12,086 shares through the vesting of RSUs, which did not involve any cash transaction. The RSUs represent a right to receive one share of the company’s common stock per unit upon settlement.
Day One Biopharmaceuticals, headquartered in Brisbane, California, is engaged in the development of new therapies for patients with life-threatening diseases. With analyst price targets ranging from $25 to $43, and the company’s next earnings report due in 4 days, InvestingPro subscribers can access additional insights and 6 more ProTips about DAWN’s financial outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.